Compare TSQ & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSQ | VTVT |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 127.0M |
| IPO Year | 2000 | 2015 |
| Metric | TSQ | VTVT |
|---|---|---|
| Price | $5.34 | $34.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $12.50 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 85.0K | 12.8K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | ★ 15.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $438,695,000.00 | $17,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | N/A |
| P/E Ratio | $4.65 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.30 | $13.15 |
| 52 Week High | $10.39 | $34.45 |
| Indicator | TSQ | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 70.36 |
| Support Level | $4.75 | $22.92 |
| Resistance Level | $4.98 | $32.53 |
| Average True Range (ATR) | 0.22 | 2.19 |
| MACD | 0.11 | 0.52 |
| Stochastic Oscillator | 89.00 | 88.25 |
Townsquare Media Inc is a radio, digital media, entertainment, and digital marketing solutions company principally focused on being the premier local advertising and marketing solutions platform in small and mid-sized markets across the United States. It has three segments which are Subscription Digital Marketing Solutions, Digital Advertising, and Broadcast Advertising. It earns the majority of the revenue from the Broadcasting Advertising segment, which includes its local, regional, and national advertising products and solutions delivered via terrestrial radio broadcast. Its portfolio includes local media brands such as WYRK.com, WJON.com, and NJ101.5.com, and premier national music brands such as XXLmag.com, TasteofCountry.com, UltimateClassicRock.com, and Loudwire.com.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.